GO:0005302 L-tyrosine transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005302 defines the molecular function that enables transfer of L-tyrosine across a membrane, a rate-limiting step for tyrosine availability in cells.
• LAT1 (SLC7A5) is a major transporter that recognizes L-tyrosine and other large neutral amino acids, and its structure explains how substrates and drugs are recognized.
• Transport activity is coupled to cellular metabolism, including insulin signaling and nutrient sensing, which affects tyrosine utilization.
• Dysregulated amino acid transport, including tyrosine uptake, is linked to cancer cell growth and drug resistance.
• Membrane trafficking and ubiquitination of transporters regulate their surface levels and therefore transport capacity.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to test causality of transporter genes in disease.
Description
L-tyrosine transmembrane transporter activity (GO:0005302) is a molecular function that enables the movement of L-tyrosine from one side of a membrane to the other. This activity is fundamental because L-tyrosine is a precursor for protein synthesis, catecholamine neurotransmitters, and thyroid hormones, and its cellular uptake must be tightly controlled. Researchers study this term to understand how cells acquire tyrosine, how transport defects contribute to metabolic and neurological disorders, and how transporter proteins can be targeted therapeutically. The function is carried out by integral membrane proteins that couple substrate binding to conformational changes, often using ion gradients or facilitated diffusion. Because tyrosine transport intersects with signaling pathways such as insulin and mTOR, it is a focal point for cancer metabolism and metabolic disease research. This article integrates the QuickGO definition with verified literature to provide a research-grade overview of GO:0005302, its mechanisms, key genes, and experimental models.
L-tyrosine transmembrane transporter activity At A Glance
| GO ID | GO:0005302 |
|---|---|
| GO term | L-tyrosine transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | L-tyrosine permease activity; L-tyrosine transporter activity; valine/tyrosine/tryptophan permease activity |
| Major function | Transfer of L-tyrosine across a membrane |
| Substrate | L-tyrosine (2-amino-3-(4-hydroxyphenyl)propanoic acid) |
| Cellular location | Plasma membrane and intracellular membranes |
| Representative genes | SLC7A5 (LAT1), SLC3A2 (4F2hc), SLC16A10, SLC43A1, SLC43A2 |
| Related diseases | Cancer, metabolic disorders, neurological conditions |
What Is GO:0005302?
GO:0005302 describes the molecular function of enabling the transfer of L-tyrosine (2-amino-3-(4-hydroxyphenyl)propanoic acid) across a membrane. It is not a description of a whole pathway or a specific protein, but rather an activity that can be carried out by multiple transporter proteins. The term includes synonyms such as L-tyrosine permease activity, L-tyrosine transporter activity, and valine/tyrosine/tryptophan permease activity, reflecting the broad substrate specificity of some transporters. In practice, annotating a gene with GO:0005302 means that experimental evidence shows the gene product can move L-tyrosine across a lipid bilayer, either by facilitated diffusion or secondary active transport.
Why Is L-tyrosine transmembrane transporter activity Important in Cell Biology?
L-tyrosine transmembrane transporter activity is critical because it controls the intracellular supply of tyrosine, which is required for protein synthesis and for the production of dopamine, norepinephrine, epinephrine, and thyroid hormones. In cancer, upregulated amino acid transporters such as LAT1 (SLC7A5) support rapid proliferation by supplying essential amino acids, and their expression correlates with poor prognosis. In metabolic disorders, altered insulin signaling can affect amino acid transport and utilization. Therefore, understanding GO:0005302 provides mechanistic insight into normal physiology and multiple diseases, and it offers a target for therapeutic intervention.
• Provides tyrosine for protein synthesis and neurotransmitter biosynthesis.
• LAT1 (SLC7A5) is overexpressed in many cancers and supports tumor growth.
• Transport activity influences insulin sensitivity and metabolic homeostasis.
• Mutations or dysregulation can contribute to neurological and metabolic diseases.
• Transporter structure guides drug design for anticancer agents.
• Membrane trafficking and ubiquitination regulate transporter surface expression.
• Tyrosine transport is coupled to mTOR signaling and cell growth.
• CRISPR models enable causal testing of transporter genes in disease.
What Happens During L-tyrosine transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs L-tyrosine from one side of the membrane.
Transporter proteins such as LAT1 (SLC7A5) form a binding pocket that specifically recognizes L-tyrosine and related large neutral amino acids. Structural studies show that the substrate binds through interactions with conserved residues, and the binding affinity determines transport efficiency. This step is the first committed event in the transport cycle and is often regulated by substrate availability.
Conformational change and translocation
In simple terms: The transporter changes shape to move tyrosine across the membrane.
Upon substrate binding, the transporter undergoes conformational changes that expose the substrate to the opposite side of the membrane. For LAT1, this involves an alternating access mechanism where the substrate is translocated through the protein. The energy for this process can come from ion gradients or from facilitated diffusion, depending on the transporter family.
Substrate release and reset
In simple terms: Tyrosine is released inside the cell, and the transporter resets for another round.
After translocation, L-tyrosine is released into the cytoplasm, and the transporter returns to its initial conformation to begin a new cycle. This step ensures continuous supply of tyrosine when extracellular concentrations are sufficient. The rate of reset can be influenced by membrane potential and ion concentrations.
Coupling to cellular metabolism
In simple terms: The transported tyrosine feeds into metabolic pathways and signaling.
Once inside the cell, L-tyrosine is used for protein synthesis and as a precursor for catecholamines and thyroid hormones. Transport activity is therefore integrated with insulin signaling and nutrient sensing pathways that regulate cell growth. Dysregulation of this coupling can lead to metabolic imbalances observed in disease.
Key Genes Involved in GO:0005302 L-tyrosine transmembrane transporter activity
The following genes encode proteins that exhibit L-tyrosine transmembrane transporter activity or regulate it, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC7A5 (LAT1) | Major transporter for large neutral amino acids including L-tyrosine | Overexpressed in cancers; structural basis for drug recognition |
| SLC3A2 (4F2hc) | Heavy chain that partners with LAT1 for surface expression | Required for LAT1 function; target for transport studies |
| SLC16A10 | Aromatic amino acid transporter | Transports tyrosine and tryptophan; linked to metabolic disorders |
| SLC43A1 | Facilitative transporter for large neutral amino acids | Expressed in liver and muscle; role in amino acid homeostasis |
| SLC43A2 | Facilitative transporter for large neutral amino acids | Potential role in immune cell metabolism |
| SLC6A19 | Neutral amino acid transporter | Mutations cause Hartnup disorder; transports tyrosine |
| SLC7A8 (LAT2) | Amino acid transporter | Broad substrate specificity including tyrosine |
| SLC7A11 | Cystine/glutamate transporter | Indirectly affects tyrosine availability |
| SLC1A5 | Neutral amino acid transporter | Supports glutamine and tyrosine uptake in cancer |
| SLC38A2 | Sodium-coupled neutral amino acid transporter | Regulates intracellular amino acid pools |
| SLC3A1 | Heavy chain for amino acid transporters | Mutations cause cystinuria; affects tyrosine transport |
| SLC7A9 | Light chain for amino acid transporters | Partners with SLC3A1; transports tyrosine |
| CD36 | Scavenger receptor | Inhibitors potentiate HER2-targeted therapy; may affect amino acid transport |
| EGFR | Receptor tyrosine kinase | Mutations and trafficking affect amino acid transport in cancers |
| CIRBP | Cold-inducible RNA-binding protein | Nuclear import linked to stress responses; may influence transport |
| TRP channels | Ion channels | Regulate calcium and amino acid transport in cystic fibrosis |
| Gap junction proteins | Intercellular channels | Ubiquitination regulates membrane protein turnover |
| Insulin receptor | Metabolic signaling | Regulates amino acid transport and utilization |
How Is L-tyrosine transmembrane transporter activity Regulated?
L-tyrosine transmembrane transporter activity is regulated at multiple levels. Transcriptional control of transporter genes such as SLC7A5 responds to nutrient availability and growth signals. Post-translational modifications, including ubiquitination, control the stability and surface expression of membrane proteins, thereby affecting transport capacity. Insulin signaling modulates amino acid transport and metabolism, linking systemic metabolic status to cellular tyrosine uptake. Additionally, membrane trafficking pathways determine whether transporters reach the plasma membrane, and mutations in trafficking regulators can alter transport activity.
L-tyrosine transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC7A5 (LAT1) | Cancer proliferation and drug resistance | Knockout and overexpression in cancer cell lines |
| SLC3A2 (4F2hc) | Cancer and immune disorders | Knock-in of tagged version for trafficking studies |
| SLC6A19 | Hartnup disorder | Point mutation knock-in in model organisms |
| EGFR | Cancer and trafficking abnormalities | Point mutation and knockout in lung cancer cells |
| CD36 | HER2-positive breast cancer | Inhibitor treatment and knockout models |
Cancer metabolism and drug resistance
Upregulation of L-tyrosine transporters, particularly LAT1 (SLC7A5), is observed in many cancers and supports the high demand for amino acids during proliferation. Structural studies of LAT1 have revealed how anticancer drugs are recognized, providing a basis for designing inhibitors that block tyrosine uptake. CD36 inhibitors have been shown to potentiate HER2-targeted therapy in HER2-positive breast cancer, suggesting that lipid and amino acid transport pathways intersect in therapeutic resistance.
Metabolic and neurological disorders
Defects in amino acid transporters can lead to metabolic imbalances. Insulin signaling regulates amino acid transport, and disruptions contribute to insulin resistance and related metabolic disorders. In the nervous system, tyrosine is a precursor for dopamine and norepinephrine, so impaired transport may affect neurotransmitter synthesis and neurological function.
Membrane trafficking and channelopathies
Mutations in EGFR affect its trafficking and downstream signaling, which can influence amino acid transport in cancers. Similarly, ubiquitination of gap junction proteins regulates their turnover, highlighting how membrane protein quality control impacts transport functions. TRP channels in cystic fibrosis modulate ion and nutrient transport, illustrating the broader context of membrane transport in disease.
From L-tyrosine transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SLC7A5 reduce tyrosine uptake? | CRISPR knockout in cancer cell lines |
| How do point mutations affect transporter function? | Point mutation knock-in using CRISPR |
| Where is the transporter localized? | Tagged knock-in with fluorescent protein |
| Does overexpression drive proliferation? | CRISPR overexpression models |
| How does EGFR mutation affect transport? | Point mutation knock-in in EGFR |
| Can transporter inhibitors reverse drug resistance? | Knockout plus inhibitor treatment |
How to Study the L-tyrosine transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Rate of L-tyrosine transport | Functional validation of transporter genes |
| Cryo-EM | High-resolution structure | Substrate and drug binding studies |
| Proteomics | Protein interactions and modifications | Identifying regulatory partners |
| Live-cell imaging | Transporter localization and dynamics | Trafficking and surface expression |
| CRISPR knockout | Loss-of-function effects | Causal testing of transporter genes |
| Point mutation knock-in | Effect of specific mutations | Disease variant modeling |
| Overexpression | Gain-of-function effects | Proliferation and drug resistance studies |
| RNA-seq | Transcriptional changes | Pathway analysis after transport perturbation |
Transport assays
Radiolabeled or fluorescent L-tyrosine uptake assays measure the rate of transport in cells or membrane vesicles. These assays can be performed in knockout or overexpression backgrounds to attribute activity to specific genes.
Structural biology
Cryo-EM and X-ray crystallography reveal the atomic structure of transporters bound to L-tyrosine or inhibitors, explaining substrate specificity and drug recognition.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify transporter complexes and post-translational modifications that regulate activity.
Live-cell imaging
Fluorescently tagged transporters enable tracking of trafficking, surface expression, and internalization in real time.
How CRISPR Can Be Used to Study GO:0005302 L-tyrosine transmembrane transporter activity
Knockout
CRISPR knockout of transporter genes such as SLC7A5 eliminates L-tyrosine transport activity, allowing researchers to measure the contribution of that gene to cellular tyrosine uptake and downstream phenotypes.
Point Mutation
Point mutation knock-in can model disease-associated variants in transporter genes, revealing how specific amino acid changes alter substrate binding or transport kinetics.
Knock-in
Knock-in of tagged transporters (e.g., GFP or HA) enables visualization and biochemical isolation of the transporter complex without altering its function.
Overexpression
CRISPR-mediated overexpression of transporters can test whether increased tyrosine uptake drives proliferation or drug resistance in cancer models.
How EDITGENE Supports L-tyrosine transmembrane transporter activity Research
Researchers studying L-tyrosine transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in tyrosine uptake, metabolic reprogramming, or disease progression. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for L-tyrosine transmembrane transporter activity research.
Frequently Asked Questions About L-tyrosine transmembrane transporter activity
What is L-tyrosine transmembrane transporter activity?
It is a molecular function (GO:0005302) that enables the transfer of L-tyrosine across a membrane, carried out by transporter proteins such as LAT1.
What genes are involved in L-tyrosine transmembrane transporter activity?
Key genes include SLC7A5 (LAT1), SLC3A2 (4F2hc), SLC16A10, SLC43A1, SLC43A2, and SLC6A19, among others.
How is L-tyrosine transported into cells?
Transporters bind L-tyrosine and undergo conformational changes to move it across the membrane, often coupled to ion gradients or facilitated diffusion.
Why is L-tyrosine transport important in cancer?
Many cancers upregulate LAT1 to meet high amino acid demands, and this supports proliferation and drug resistance.
What diseases are linked to defective tyrosine transport?
Metabolic disorders, neurological conditions, and cancer have been associated with altered tyrosine transport.
How can CRISPR help study L-tyrosine transporters?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of transporter genes in cellular and disease phenotypes.
What methods measure L-tyrosine transport activity?
Radiolabeled uptake assays, structural biology, proteomics, and live-cell imaging are commonly used.
Is LAT1 the only L-tyrosine transporter?
No, multiple transporters including SLC16A10, SLC43A1, and SLC6A19 can transport L-tyrosine.
How is L-tyrosine transporter activity regulated?
It is regulated by transcription, post-translational modifications such as ubiquitination, and membrane trafficking.
Can EDITGENE create custom models for tyrosine transporter research?
Yes, EDITGENE offers knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to GO:0005302.
Conclusion
L-tyrosine transmembrane transporter activity (GO:0005302) is a fundamental molecular function that controls the cellular supply of tyrosine, impacting protein synthesis, neurotransmission, and metabolism. Dysregulation of this activity is implicated in cancer, metabolic disorders, and neurological conditions, making it a compelling target for research and therapeutic development. By leveraging CRISPR-based models and advanced analytical methods, researchers can dissect the precise roles of individual transporters and their regulatory networks.
References
- 2. Lee Y et al.. 2025. Structural basis of anticancer drug recognition and amino acid transport by LAT1.. Nat Commun 16(1):1635 PMID: 39952931
- 3. Castagnoli L et al.. 2025. Identification of new selective CD36 inhibitors to potentiate HER2-targeted therapy in HER2-positive breast cancer.. Sci Rep 15(1):28709 PMID: 40770043
- 4. Kang X et al.. 2024. EGFR mutations and abnormal trafficking in cancers.. Mol Biol Rep 51(1):924 PMID: 39167290
- 6. Merheb E et al.. 2026. Biochemistry, Insulin Metabolic Effects.. PMID: 30252239
- 7. Grebert C et al.. 2019. Focus on TRP channels in cystic fibrosis.. Cell Calcium 81:29-37 PMID: 31176886
- 8. Leithe E et al.. 2007. Ubiquitination of gap junction proteins.. J Membr Biol 217(1-3):43-51 PMID: 17657522
